Thomas, Anish

Antibody–drug conjugates for cancer therapy

Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology

Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins

Cited by 606

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 233

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 172

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 94

Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial

Abel, M. L., Takahashi, N., Desai, P., Peer, C., Redon, C., Nichols, S., Vilimas, R., Lee, M.-J., Lee, S., Sciuto, L., et al. (2023) · Cancer Research

Cancer therapeutics and mechanismsPARP inhibition in cancer therapy

Cited by 4